<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511702</url>
  </required_header>
  <id_info>
    <org_study_id>HZNP-KRY-403</org_study_id>
    <nct_id>NCT04511702</nct_id>
  </id_info>
  <brief_title>Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate</brief_title>
  <official_title>A Phase 4, Multicenter, Open-Label, Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horizon Therapeutics Ireland DAC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Horizon Pharma Ireland, Ltd., Dublin Ireland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the tolerability of pegloticase administered with a&#xD;
      shorter infusion duration in participants with uncontrolled gout receiving methotrexate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 30-50 participants will be enrolled. After a 4-week methotrexate run-in period,&#xD;
      participants will be treated for up to 24 weeks with weekly oral methotrexate and biweekly&#xD;
      8mg pegloticase infusions. Up to three pegloticase infusion durations will be assessed in the&#xD;
      study: 60-minute infusion, 45-minute infusion and 30-minute infusion. Safety evaluations will&#xD;
      be performed regularly throughout the course of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Three different infusion durations may be used. 60-minute infusion, 45-minute infusion and 30-minute and each will include 10 participants.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of participants experiencing Infusion Reactions (IRs), including anaphylaxis related to pegloticase</measure>
    <time_frame>Day 1 through Week 24.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who experienced any of the following events: infusion reaction leading to discontinuation of treatment, anaphylaxis, or meeting Individual participant sUA Discontinuation Criteria</measure>
    <time_frame>Day 1 to Week 24</time_frame>
    <description>A participant meets the Individual participant sUA Discontinuation Criteria if he or she has a pre-infusion sUA level &gt;6 mg/dL at 2 consecutive study visits beginning with the Week 2 Visit. When this occurs, the participants must discontinue treatment, with the option to continue on the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to any of the following events: infusion reaction leading to discontinuation of treatment, anaphylaxis, or meeting Individual participant sUA Discontinuation Criteria</measure>
    <time_frame>Day 1 to Week 24</time_frame>
    <description>A participant meets the Individual participant sUA Discontinuation Criteria if he or she has a pre-infusion sUA level &gt;6 mg/dL at 2 consecutive study visits beginning with the Week 2 Visit. When this occurs, the participants must discontinue treatment, with the option to continue on the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who experienced infusion reaction leading to slowing down of the infusion rate or discontinuation of treatment</measure>
    <time_frame>Day 1 to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first infusion reaction leading to slowing down of the infusion rate or discontinuation of treatment</measure>
    <time_frame>Day 1 to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first infusion reaction</measure>
    <time_frame>Day 1 to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who were able to complete all infusions over the assigned treatment duration length or a lesser time, without clinically requiring an increased infusion time</measure>
    <time_frame>Day 1 to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of infusions completed over the assigned duration length or a lesser time, without clinically requiring an increased infusion time</measure>
    <time_frame>Day 1 to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Uncontrolled Gout</condition>
  <condition>Gout</condition>
  <condition>Uncontrolled Gout</condition>
  <arm_group>
    <arm_group_label>Pegloticase 60 Minute Infusion with methotrexate (MTX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegloticase 60 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegloticase 45 Minute Infusion with methotrexate (MTX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegloticase 45 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegloticase 30 Minute Infusion with methotrexate (MTX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegloticase 30 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegloticase with MTX</intervention_name>
    <description>Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period</description>
    <arm_group_label>Pegloticase 30 Minute Infusion with methotrexate (MTX)</arm_group_label>
    <arm_group_label>Pegloticase 45 Minute Infusion with methotrexate (MTX)</arm_group_label>
    <arm_group_label>Pegloticase 60 Minute Infusion with methotrexate (MTX)</arm_group_label>
    <other_name>Methotrexate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult men or women ≥18 years of age.&#xD;
&#xD;
          2. Uncontrolled gout, defined as meeting the following criteria:&#xD;
&#xD;
               -  Hyperuricemia during the screening period defined as sUA ≥6 mg/dL&#xD;
&#xD;
               -  Failure to maintain normalization of sUA with xanthine oxidase inhibitors at the&#xD;
                  maximum medically appropriate dose, or with intolerable side effects or a&#xD;
                  contraindication to xanthine oxidase inhibitor therapy based on medical record&#xD;
                  review or subject interview&#xD;
&#xD;
               -  Symptoms of gout including at least 1 of the following:&#xD;
&#xD;
                    -  Presence of at least one tophus&#xD;
&#xD;
                    -  Recurrent flares defined as 2 or more flares in the past 12 months prior to&#xD;
                       screening&#xD;
&#xD;
                    -  Presence of chronic gouty arthritis&#xD;
&#xD;
          3. Willing to discontinue all oral urate-lowering therapy at least 7 days prior to MTX&#xD;
             dosing at Week -4 and remain off of urate lowering therapy when receiving pegloticase&#xD;
             infusions during the study.&#xD;
&#xD;
          4. Able to tolerate MTX 15 mg for 4 weeks during the MTX Run-in Period prior to the first&#xD;
             dose of pegloticase.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current or chronic treatment with systemic immunosuppressive agents such as&#xD;
             MTX,azathioprine, or mycophenolate mofetil; prednisone ≥10 mg/day or equivalent dose&#xD;
             of other corticosteroid on a chronic basis (defined as 3 months or longer) would also&#xD;
             meet exclusion criteria.&#xD;
&#xD;
          2. Known history of any solid organ transplant surgery requiring maintenance&#xD;
             Immunosuppressive therapy unless treated and no chronic or active infection confirmed&#xD;
             by HBV serology.&#xD;
&#xD;
          3. Known history of hepatitis B virus surface antigen positivity or hepatitis B DNA&#xD;
             positivity, unless treated and viral load is negative and no chronic or active&#xD;
             infection confirmed by HBV serology.&#xD;
&#xD;
          4. Known history of Human Immunodeficiency Virus (HIV) positivity.&#xD;
&#xD;
          5. Glucose-6-phosphate dehydrogenase (G6PD) deficiency (tested at Screening Visit).&#xD;
&#xD;
          6. Severe chronic renal impairment (estimated glomerular filtration rate &lt;40 mL/min/1.73&#xD;
             m2) at the Screening Visit based on 4 variable-Modification of Diet in Renal Disease&#xD;
             [MDRD] formula or currently on dialysis.&#xD;
&#xD;
          7. Non-compensated congestive heart failure or hospitalization for congestive heart&#xD;
             failure or treatment for acute coronary syndrome (myocardial infarction or unstable&#xD;
             angina) within 3 months of the Screening Visit, or current uncontrolled arrhythmia, or&#xD;
             current uncontrolled blood pressure (BP) (&gt;160/100 mmHg) prior to Week -4.&#xD;
&#xD;
          8. Pregnant, planning to become pregnant, breastfeeding, planning to impregnate female&#xD;
             partner, or not on an effective form of birth control, as determined by the&#xD;
             Investigator.&#xD;
&#xD;
          9. Prior treatment with pegloticase (KRYSTEXXA), another recombinant uricase&#xD;
             (rasburicase), or concomitant therapy with a polyethylene glycol-conjugated drug.&#xD;
&#xD;
         10. Known intolerance to MTX.&#xD;
&#xD;
         11. Chronic liver disease.&#xD;
&#xD;
         12. Currently receiving systemic or radiologic treatment for ongoing cancer.&#xD;
&#xD;
         13. History of malignancy within 5 years other than non-melanoma skin cancer or in situ&#xD;
             carcinoma of cervix.&#xD;
&#xD;
         14. Known history of hypoxanthine-guanine phosphoribosyl-transferase deficiency, such as&#xD;
             Lesch-Nyhan and Kelley-Seegmiller syndrome.&#xD;
&#xD;
         15. Current pulmonary fibrosis, bronchiectasis or interstitial pneumonitis. If deemed&#xD;
             necessary by the Investigator, a chest X-ray may be performed during Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Supra Verma, MD</last_name>
    <role>Study Director</role>
    <affiliation>Horizon Therapeutics Ireland DAC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HorizonTherapeutics</last_name>
    <phone>1-866-479-6742</phone>
    <email>clinicaltrials@horizontherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orthopedic Physicians Alaska</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Campione</last_name>
      <phone>907-341-5220</phone>
      <email>acampione@opaak.com</email>
    </contact>
    <investigator>
      <last_name>John Botson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amicis Research Center</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tyrone Rosales</last_name>
      <phone>818-924-4708</phone>
      <email>Tyrone.rosales@amicisresearch.com</email>
    </contact>
    <investigator>
      <last_name>Pascal Dabel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Tujunga</city>
        <state>California</state>
        <zip>91042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Robleto</last_name>
      <phone>213-281-5146</phone>
      <email>melanie@medvinresearch.com</email>
    </contact>
    <investigator>
      <last_name>Dan La, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Denver Arthritis Clinic</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Hernandez</last_name>
      <phone>303-394-2828</phone>
      <phone_ext>177</phone_ext>
      <email>thernandez@dacdenver.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Antolini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Napa Research Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magda Hernandez</last_name>
      <phone>305-960-7934</phone>
      <email>mhernandez@napatrials.com</email>
    </contact>
    <investigator>
      <last_name>Naval Parikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GCP Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlene Klingeman</last_name>
      <phone>321-315-0780</phone>
      <email>marlenek@gcpclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Karon Locicero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Medical Research</name>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <zip>20745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Edwards</last_name>
      <phone>301-329-2608</phone>
      <email>marie.edwards@mdmedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Ong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Hickory, LLC</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Everhart</last_name>
      <phone>828-345-5060</phone>
      <email>nicole.everhart@pmg-research.com</email>
    </contact>
    <investigator>
      <last_name>Dennis Payne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury, LLC</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Smith</last_name>
      <phone>704-647-9913</phone>
      <email>stacy.smith@pmg-research.com</email>
    </contact>
    <investigator>
      <last_name>Rakesh Patel, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shelby Clinical Research, LLC</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Seagle</last_name>
      <phone>980-552-9230</phone>
      <email>pseagle@shelbyclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Morrison</last_name>
      <phone>814-693-0300</phone>
      <phone_ext>144</phone_ext>
      <email>pammorrison@altoonaresearch.com</email>
    </contact>
    <investigator>
      <last_name>Alan Kivitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abigail Rebecca Neiman, MD, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassan Arshad</last_name>
      <phone>713-932-0054</phone>
      <email>Hassan@biopharmainfo.net</email>
    </contact>
    <investigator>
      <last_name>Abigail R Neiman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Cone</last_name>
      <phone>509-838-6500</phone>
      <phone_ext>310</phone_ext>
      <email>tcone@arthritisnw.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Butler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gout</keyword>
  <keyword>uncontrolled gout</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

